V. Indihar

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials”.

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(22)00504-5

N/A

1.5DataRank · unranked

67 citations

Gordon MacGregor, Pilar Azevedo, V. Indihar, Claire Keating, Marcus Mall +77 more

27 Effect of SARS-CoV-2 on long-term physical and mental health symptoms in people with cystic fibrosis and their caregivers

Journal of Cystic Fibrosis(2022)10.1016/s1569-1993(22)00718-4

N/A

0DataRank · unranked

0 citations

P. Cheng, J. Chmiel, C. Brown, E. Kramer, V. Indihar +5 more

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.008

N/A

0DataRank · unranked

144 citations

Jonathan B. Zuckerman, Daniel Dorgan, Jorge Lascano, Karen McCoy, Manu Jain +15 more